se gb

Torbjörn Bjerke appointed Chairman of Pergamum AB

Torbjörn Bjerke, Chief Executive Officer, Karolinska Development AB (publ), was appointed Chairman of the Board of Directors following the Annual Shareholders’ Meeting in Pergamum AB on June 22, 2011.

"Several of Pergamum's development initiatives have the potential of changing future medical practice in the area of dermatology and wound healing. The company is an important part of the Karolinska Development portfolio and I look forward to working with the Board and management team to take the company and its three main development programs forward", says Torbjörn Bjerke.

"Pergamum has a number of important transitions ahead. With two projects in Phase II and a third about to enter clinical development, the focus on business development is increasing. A key to success is a strong, cohesive board of directors devoted to the mission to find partners for its most advanced projects. With his strong deal making track record, I cannot think of a better Chairman for Pergamum than Torbjörn Bjerke at this juncture and I am grateful to have the opportunity to work under his guidance", says Jonas Ekblom, CEO of Pergamum.

For more information, please contact:
Jonas Ekblom, CEO, Phone: +46 (0)8 470 37 40, E-mail:

About Pergamum
Pergamum is a biopharmaceutical company, with headquarters in Stockholm, that is specialized in the development of innovative drugs for the treatment of wounds and skin infections. The company is currently conducting a number of research and development programs, several being at clinical stage.


pdf.png Torbjörn Bjerke appointed Chairman of Pergamum AB